Raloxifene, a selective estrogen receptor modulator that differentially activates or blocks estrogenic pathways in a tissue-specific manner (National Institute of Diabetes Digestive Kidney Diseases, 2012), exhibited substantial similarities in both regulatory directions. Here, ESR1 is linked to kidney disorder.